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Synthesis of thiophene and N-substituted thieno[3,2-d]
pyrimidine derivatives as potent antitumor 
and antibacterial agents
A novel series of carbamothioylamino-benzene-sulfonamide-
thiophene-carboxylates 4a-c and thieno[3,2-d]pyrimidin-2-
yl-amino-benzene-sulfonamides 5a-c were synthesized in a 
series of synthetic steps and were used as key intermediates 
for the synthesis of thienotriazolopyrimidine-benzene-sul-
fonamide derivatives 6a-c and 7a-c. Thieno[3,2-d]pyrimidin-
ones (8 and 9) were also prepared. Compound 9 was used as 
an intermediate for the synthesis of imidazole/1,2,4-triazole 
and tetrazine functionalized thieno[3,2-d]pyrimidine deriva-
tives (10–12). Pyrrole derivatives/pyrrolopyrimidine/pyrrolo-
triazolopyrimidine functionalized thiophenes (15–19) were 
also synthesized. Structures of the newly synthesized com-
pounds were established by elemental analysis and spectral 
data. Most of the newly synthesized compounds were evalu-
ated for their in vitro activity against three human tumor cell 
lines, namely, liver cancer (HepG-2), colon cancer (HT-29) and 
lung cancer (NCI-H460), using doxorubicin as standard. 
Compounds 16 (GI50 = 0.02, 0.04 and 0.06 μmol L–1, resp.) and 
19b (GI50 = 0.02, 0.03 and 0.05 μmol L–1, resp.) showed higher 
activity against all cell lines than doxorubicin. Most of the 
compounds were also screened for antibacterial activity using 
ciprofl oxacin as standard drug. Compounds 4b and 6b, both 
containing benzenesulfonamide linked to N-, 10 bearing imi-
dazole moiety, and 15 and 19b,c with a thiophene-2-carboxylic 
acid chain, exhibited high activity against Gram-positive and 
Gram-negative bacteria.
Keywords:  thieno[3,2-d]pyrimidines, thieno[3,2-d][1,2,4]tri-
azolo[1,5-a]pyrimidines, anticancer, antibacterial
Thiophene derivatives are among the most important chemotherapeutic agents and 
are widely used (1, 2). Thienopyrimidines occupy a special position among condensed 
heterocyclic compounds. They have been widely employed due to their activities as anti-
tumor (3, 4), antimetabolite (5), antiviral, anti-HIV-1 (6), antiproliferative (7), antimicrobial 
(10, 11), analgesic and anti-infl ammatory (12, 13) agents, as well as kinase (8) and phospho-
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diesterase IV inhibitors (9). Among these active compounds, thieno[3,2-d]pyrimidines 
have generated wide-spread interest due to their remarkable antitumor activities (3, 4, 14). 
Thus, substituted thieno[3,2-d]pyrimidines exert pronounced activity as PI3K inhibitors 
(GDC-0941) and EGFR and VEGFR dual inhibitors, which are used in the treatment of 
cancers (15–17). As a part of our continuing program on the synthesis of antimicrobial and 
antitumor compounds, we have earlier reported on a series of heterocyclic moieties that 
have biological activities (11–13).
Furthermore, sulfonamide derivatives are an important class of compounds used as 
scaff olds in medicinal chemistry (11) in addition to triazole derivatives (18), showing anti-
bacterial (19), antineoplastic (20) and antitubercular (21) activity. Recently, compounds 
bearing 1,2,4-triazole moieties have att racted great att ention owing to their anticancer 
value (22, 23). The present work is an extension of our ongoing eff orts towards the synthe-
sis and evaluation of novel thiophenes bearing biologically active sulfonamide, pyrole, 
pyrrolopyrimidine derivatives, and thieno[3,2-d]pyrimidine derivatives containing 
1,2,4-triazole moiety, as antitumor and antibacterial agents.
EXPERIMENTAL
An Electrothermal 9100 series digital melting point apparatus (Shimadzu, Japan) was 
used for all measurements of melting points. For microanalytical data, a Vario Elementar 
apparatus (Shimadzu) was used. Elemental analyses of all compounds were within ± 0.4 % 
of theoretical values. IR spectra (KBr) were recorded on a Perkin Elmer 1650 spectrometer 
(USA) while 1H NMR and 13C NMR spectra were recorded on JEOL EX-300 and JEOL ECA-
500 (Shimadzu) instruments, resp. Chemical shift s were expressed in ppm relative to 
SiMe4 as internal standard in DMSO-d6 as solvent. For mass spectra recording, a 70 eV 
Finnigan SSQ 7000 spectrometer (Thermo-Instrument System Incorporation, USA) was 
used. Purity of the compounds was checked by TLC using silica gel-coated aluminum 
plates (Merck, Germany). 3-Amino-5-(4-chlorophenyl)-thiophene-2-carboxylic acid (1) and 
other chemicals and solvents (Analar ≥ 99%) were purchased from Sigma-Aldrich (USA). 
Ciprofl oxacin and doxorubicin disks were supplied by the Pasteur Laboratory (Egypt).
Syntheses
Ethyl 3-amino-5-(4-chlorophenyl)-thiophene-2-carboxylate (2). – 3-Amino-5-(4-
chlorophenyl)-thiophene-2-carboxylic acid (1, 15 g, 60 mmol) was suspended in 150 mL of 
absolute ethyl alcohol (99 %). Dry hydrogen chloride was passed through until the solu-
tion was saturated and became hot, then the reaction mixture was refl uxed for 2 h. When 
the reaction was complete, the solution was cooled and the mixture was diluted with 200 
mL of water and made alkaline by sodium carbonate solution. A solid product crystal-
lized from ethanol as white crystals.
Ethyl 5-(4-chlorophenyl)-3-isothiocyanatothiophene-2-carboxylate (3). – A mixture of com-
pound 2 (2.81 g, 10 mmol) and thiophosgene (1.14 mL, 10 mmol) in dry chloroform (25 mL) 
was stirred under refl ux for 6 h. The solvent was evaporated and the solid obtained was 
recrystallized from ethanol as a deep yellow solid.
277
H. N. Hafez et al.: Synthesis of thiophene and N-substituted thieno[3,2-d]pyrimidine derivatives as potent antitumor and antibacterial 
agents, Acta Pharm. 67 (2017) 275–292.
 
Ethyl-5-(4-chlorophenyl)-3-[N-(substituted) 4-(carbamothioyl)amino-benzenesulfonamide] 
thiophene-2-carboxylate derivatives (4a-c). General procedure. – A mixture of compound 3 (3.24 
g, 10 mmol) and 0.01 mol of the appropriate sulfa drug (sulfaguanidine, 2,6-dimethoxysul-
fadiazine or 3,4-dimethylsulfaiso-oxazole) in DMF (30 mL) was stirred under refl ux for 5 h. 
The reaction mixture was poured onto ice water and the obtained product was recrystal-
lized from dioxane to give compounds 4a-c. The following compounds were prepared: 










2 C13H12ClNO2S (281.7) 108–110 65 55.42   55.40 4.29    4.28   4.97     4.94
3 C14H10ClNO2S2 (323.8) 165–167 70 51.93   51.90 3.11    3.09   4.33     4.32
4a C21H20ClN5O4S3 (538) 210–212 60 46.88   46.86 3.75    3.74 13.00   13.02
4b C26H24ClN5O6S3 (634.1) 230–232 63  49.24    49.22 3.81     3.79 11.04    11.03
4c C25H23ClN4O5S3 (591.1) 238–240 70  50.80    50.78 9.48     9.45  3.92      3.90
5a C19H16ClN7O3S2 (489.9) 254–256 83 46.58   46.55 3.29    3.25 20.01   19.98
5b C24H20ClN7O5S2 (586) 268–270 70 49.19   49.16 3.44    3.42 16.70   16.73
5c C23H21ClN6O4S2 (545) 282–284 60 50.68   50.64 3.88    3.86 15.42   15.40
6a C26H17ClFN7O3S2 (594) >300   62 52.57   52.53 2.88    2.86 16.51   16.48
6b C31H21ClFN7O5S2 (690.1) >300 65 53.95   53.91 3.07    3.05 14.21   14.18
6c C30H20ClFN6O4S2 (647.1) >300 66 55.68   55.64 3.12    3.10 12.99   12.95
7a C20H14ClN7O3S2 (499.9) 218–220 73 48.05   48.01 2.82    2.80 19.61   19.58
7b C25H18ClN7O5S2 (596) 211–213 59 50.38   50.34 3.04    3.02 16.45   16.42
7c C24H17ClN6O4S2 (553) 234–236 66 52.12   52.10  3.10    3.07 15.20   15.16
8 C19H13ClN2OS (352.8) 230–232 60 64.68   64.64 3.71    3.69   7.94     7.92
9 C12H8ClN3OS (277.7 ) 225–227 75 51.90   51.87 2.90    2.88 15.13   15.10
10 C28H17ClN4O2S (508.9 ) 253–255 66 66.07   66.04 3.37    3.35 11.01   10.99
11 C13H7ClN4S2 (318.8 ) 289–291 86 48.98   48.95 2.21    2.18 17.57   17.55
12 C24H12Cl2N6S2 (519.4 ) >330 64 55.50   55.48 2.33    2.30 16.18   16.16
13 C12H8ClN3S2 (293.7) 262–264 75 49.06   49.02 2.74    2.72 14.30   14.27
14 C19H14ClNO3S (371.8) 208–210 75 61.37   61.34 3.79    3.75   3.77     3.73
15 C22H14ClN3O2S (419.8) 180–182 70 62.93   62.90 3.36    3.34 10.01    9.98
16 C24H16ClN3O3S (461.9) 234–236 65 62.40   62.38 3.49    3.44   9.10     9.07
17 C26H16ClN3O4S (501.9) 250–252 76 62.21     62.18 3.21     3.19    8.37     8.33
18 C25H18ClN3O3S (475.9) 238–240 65 63.09   63.05 3.81    3.79    8.83     8.80
19a C30H18ClN5O2S (548) 266–268 60 65.75   65.72 3.31    3.29 12.78   12.74
19b C30H17Cl2N5O2S (582.4) 284–286 73 61.86   61.82 2.94    2.91 12.02   12.00
19c C31H20ClN5O3S (578.0) 279–281 68 64.41   64.38 3.49    3.46 12.12   12.09
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ethyl 5-(4-chlorophenyl)-3-[N-carbamimidoyl-4-(carbamothioyl)amino-benzene-sulfon-
amide]thiophene-2-carboxylate (4a), ethyl 5-(4-chlorophenyl)-3-[N-(2,6-dimethoxypyrimi-




substituted benzenesulfonamide derivatives (5a-c). General procedure. – A mixture of 4a-c (10 
mmol) and hydrazine hydrate (10 mL) in butanol (30 mL) was refl uxed for 5 h. Aft er cooling, 
the reaction mixture was poured onto ice water and the solid obtained was recrystallized 
from dioxane to give 5a-c. The following compounds were prepared: 4-{[3-amino-6-(4-
chlorophenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]amino}-N-carbamimidoylben-
zenesulfonamide (5a), 4-{[3-amino-6-(4-chlorophenyl)-4-oxo-3,4-dihydrothieno[3,2-d]py-
rimidin-2-yl]amino}-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide (5b) and 
4-{[3-amino-6-(4-chlorophenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]amino}-N-
(3,4-dimethyl-1,2-oxazol-5-yl) benzene sulfonamide (5c).
7-(4-Chlorophenyl)-2-(4-fl uorophenyl)-1-(N-substituted)benzenesulfonamide thieno[3,2-d]
[1,2,4]triazolo[1,5-a]pyrimidine-5(1H)-thione (6a-c). General procedure. – A mixture of 5a-c (10 
mmol) and 4-fl uorobenzaldehyde (1.24 g, 10 mmol) in glacial acetic acid (20 mL) containing 
fused sodium acetate (0.5 g) was heated under refl ux for 6 h. The solvent was concentrated 
and the residue was recrystallized from dioxane to give 6a-c. The following compounds 
were prepared: 7-(4-chlorophenyl)-2-(4-fl uorophenyl)-1-(N-carbamimidoylbenzenesulfon-
amide) thieno[3,2-d] [1,2,4]triazolo[1,5-a]pyrimidine-5(1H)-thione (6a), 7-(4-chlorophenyl)-2-
(4-fl uorophenyl)-1-(N-(2,6-dimethoxypyrimidin-4-yl) benzenesulfonamide thieno[3,2-d]
[1,2,4] triazolo[1,5-a] pyrimidine-5(1H)-thione (6b) and 7-(4-chlorophenyl)-2-(4-fl uorophenyl)-
1-(N-(3,4-dimethyl-1,2-oxazol-5-yl) benzenesulfonamide thieno[3,2-d][1,2,4]triazolo[1,5-a] 
pyrimidine-5(1H)-thione (6c).
N-substituted-4-[7-(4-chlorophenyl)-5–oxothieno[3,2-d][1,2,4]triazolo[1,5-a]pyrimidine-
1(5H)-yl)]-benzenesulfonamide (7a-c). General procedure. – A solution of compound 5a-c (10 
mmol) in formic acid (20 mL) was heated under refl ux for 10 h. The solvent was evaporated 
under vacuum and the residue was recrystallized from ethanol to give 7a-c. The following 
compounds were prepared: N-carbamimidoyl-4-[7-(4-chlorophenyl)-5–oxothieno[3,2-d]
[1,2,4]triazolo[1,5-a] pyrimidine-1(5H)-yl)]-benzenesulfonamide (7a), 4-[7-(4-chlorophenyl)-
5-oxothieno[3,2-d][1,2,4] triazolo [1,5-a]pyrimidine-1(5H)-yl)]-(1-(N-2,6-dimethoxypyrimi-
din-4-yl)-benzenesulfonamide (7b) and 4-[7-(4-chlorophenyl)-5-oxothieno[3,2-d][1,2,4]
triazolo[1,5-a] pyrimidine-1(5H)-yl)]-(1-(N-(3,4-dimethyl[1,2]isooxazol-5-yl)-benzenesul-
fonamide (7c).
3-Benzyl-6-(4-chlorophenyl)-thieno[3,2-d]pyrimidin-4(2H)-one (8). – A mixture of com-
pound 2 (2.81 g, 10 mmol) and benzylamine (1.07 g, 10 mmol) in decalin (2.7 mL, 20 mmol) 
and triethylorthoformate (15 mL) was refl uxed for 16 h, the reaction mixture was cooled 
and fi ltered, the obtained solid was crystallized from ethanol as a pale-yellow powder.
3-Amino-6-(4-chlorophenyl)-thieno[3,2-d]pyrimidin-4(3H)-one (9). – A mixture of com-
pound 2 (2.81 g, 10 mmol), hydrazine hydrate (98 %, 2 mL) in absolute ethanol and triethy-
lorthoformate (10 mL) was refl uxed for 10 h, the reaction mixture was cooled and fi ltered. 
The obtained solid was crystallized from ethanol as a pale-brown powder.
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6-(4-Chlorophenyl)-3-(5-benzylidene-2-phenyl-3,5-dihydro-4H-imidazol-4-one-3-yl)
thieno[3,2-d]pyrimidin-4(3H)-one (10). – A mixture of compound 9 (2.78 g, 10 mmol), and 
4-benzylidene-2-phenyl-4H-oxazol-5-one (2.49 g, 10 mmol) in glacial acetic acid (20 mL) 
containing fused sodium acetate (2 g) was refl uxed for 5 h. The reaction mixture was 
cooled and then poured onto cold water, the solid obtained was crystallized from DMF as 
a white powder.
8-(4-Chlorophenyl)-thieno[2,3-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione (11). – A 
mixture of compound 9 (2.78 g, 10 mmol) and thiourea (0.76 g, 10 mmol) was fused over an 
oil bath at 220 °C for 30 min. The solid thus obtained was crystallized from ethanol as a 
yellow powder.
Bis-6,6’-(4-dichlorophenyl)-thieno[2,3-e]pyrimido[3,4-c][1,2,4,5]tetrazine (12) (24). – A mix-
ture of compound 9 (2.78 g, 10 mmol) and phosphorous pentasulfi de (2.66 g, 12 mmol) in 
pyridine (20 mL) was refl uxed for 12 h, the reaction mixture was concentrated and allowed 
to cool. The solid obtained was crystallized from ethanol as a white powder.
3-Amino-6-(4-chlorophenyl)-thieno[3,2-d]pyrimidin-4(3H)-thione (13). – A mixture of 9 
(2.78 g, 10 mmol) and phosphorous pentasulfi de (2.66 g, 12 mmol) in xylene (25 mL) was 
heated under refl ux for 5 h. The reaction mixture was hot fi ltered, the solid that separated 
from the fi ltrate crystallized from ethanol as a yellow powder.
5-(4-Chlorophenyl)-3-[(2-oxo-2-phenylethyl)-amino]thiophene-2-carboxylic acid (14). – A 
mixture of thiophene derivative 1 (2.53 g, 10 mmol) and phenacyl bromide (1.99 g, 10 mmol) 
was refl uxed in ethanol for 3 h. The solid obtained was fi ltered and crystallized from di-
oxane to give 14 as an orange powder.
3-(2-Amino-3-cyano-4-phenyl-1H-pyrrol-1-yl)-5-(4-chlorophenyl)-thiophene-2-carboxylic 
acid (15). – A mixture of 14 (3.71 g, 10 mmol) and malononotrile (0.66 g, 10 mmol) in ethanol 
(30 mL) containing sodium ethoxide (0.5 g) was refl uxed for 5 h, the reaction mixture was 
cooled and acidifi ed with dil. HCl. The solid obtained was recrystallized from dioxane to 
give 15 as pale-yellow crystals.
5-(4-Chlorophenyl)-3-(2-methyl-4-oxo-5-phenyl-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine-
7-yl)-thiophene-2-carboxylic acid (16). – A solution of 15 in acetic anhydride (30 mL) was re-
fl uxed for 8 h, the reaction mixture was concentrated under reduced pressure and the 
solid obtained was crystallized from ethanol to give 16 as a white powder.
3-(3-Cyano-2-(2,5-dioxopyrrolidin-1-yl)-4-phenyl-1H-pyrrol-1-yl)-5-(4-chlorophenyl)-thio-
phene-2-carboxylic acid (17). – A mixture of 15 (4.19 g, 10 mmol) and succinic anhydride (1.10 
g, 10 mmol) was fused at 220 °C in an oil bath for 15 min. The reaction mixture was tritu-
rated with ethanol and the solid obtained was crystallized from methanol to give 17 as 
brown crystals.
3-(3-Cyano-2-amino(ethoxymethylene)-4-phenyl-1H-pyrrol-1-yl)-5-(4-chlorophenyl)-thio-
phene-2-carboxylic acid (18). – To a mixture of triethylorthoformate (1.48 g, 10 mmol) and 
acetic anhydride (20 mL), compound 15 (4.19 g, 10 mmol) was added and the reaction mix-
ture was refl uxed for 5 h. The solvent was removed under reduced pressure and the sepa-
rated solid was recrystallized from dioxane, to give 18 as a yellow powder.
5-(4-Chlorophenyl)-{3-(4-substitutedphenyl)-9-phenyl-7H-pyrrolo[3,2-e][1,2,4] triazolo[4,3-
c]- pyrimidin-7-yl}- thiophene-2-carboxylic acid (19a-c). General procedure. – To a solution of 18 
(4.75 g, 10 mmol) in absolute ethanol (50 mL), hydrazide derivative (10 mmol) was added. 
The reaction mixture was refl uxed for 4 h, concentrated, cooled and the solid product that 
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separated was fi ltered off  and recrystallized from appropriate solvent to give 19a-c. The 
following compounds were prepared: 5-(4-chlorophenyl)-3-(3,9-diphenyl-7H-pyrrolo[3,2-e]
[1,2,4] triazolo[4,3-c]-pyrimidin-7-yl)-thiophene-2-carboxylic acid (19a), 5-(4-chlorophenyl)-
{3-(4-chlorophenyl)-9-phenyl-7H-pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]-pyrimidin-7-yl}-thio-
phene-2-carboxylic acid (19b) and 5-(4-chlorophenyl)-{3-(4-methoxyphenyl)-9-phenyl-7H-
pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]-pyrimidin-7-yl}-thiophene-2-carboxylic acid (19c).
Biological screening
Antitumor activity. – The majority of newly synthesized compounds were tested for 
in vitro anticancer activity against three human cancer cell lines [liver cancer (HepG-2), 
colon cancer (HT29) and lung cancer (NCI-H460)] using the MTT assay. The three human 
cancer cell lines were provided by the National Cancer Institute (NCI, Cairo, Egypt). 
Their growth as a monolayer was maintained in RPMI-1640 medium supplemented with 
5 % heat inactivated FBS (fetal bovine serum), 2 mmol L–1 glutamine and antibiotics 
(penicillin 100 U mL–1, streptomycin 100 μg mL–1) at 37 °C. Exponentially growing cells 
were obtained by plating 1.5 x 105 cells mL–1, followed by 24-h incubation. The eff ect of 
the solvent DMSO on cell growth was evaluated by exposing untreated control cells to 
the maximum concentration of DMSO (0.5 %) used in each assay. Eff ects of the com-
pounds on in vitro growth of human tumor cell lines was evaluated according to the 
procedure of the National Cancer Institute (NCI, USA), using sulforhodamine B as pro-
tein binding dye to assess cell growth (25). Cells growing exponentially in 96-well plates 
were then exposed for 48 h to fi ve serial concentrations of each compound, starting from 
a maximum concentration of 150 μmol L–1. Aft er this exposure period, adherent cells 
were fi xed, washed and stained. The bound stain was solubilized, the absorbance was 
measured and the growth inhibition of 50 % (GI50) was calculated (26). Doxorubicin was 
used as a reference compound (Table III).
Antibacterial activity. – Antibacterial activity of the newly synthesized compounds was 
tested in vitro against the Gram-positive bacteria Staphylococcus aureus ATCC-1096, Strepto-
coccus bovis ATCC-1030 and Gram-negative bacteria Chlamydia pneumoniae ATCC-1416 and 
Salmonella typhi ATCC 2453. All microorganisms were purchased from the American Type 
Culture Collection (Manassas, USA). The compounds were dissolved in DMSO and pre-
liminarily tested for antibacterial activity using the agar disk diff usion technique (27), 
microplate-wells (1 cm in diameter) and a solution of 100 μg mL–1 of the test compound. 
Compound-impregnated disks were placed on an agar plate containing a standard sus-
pension of microorganisms. The plate was incubated for 24 h at 37 °C. Diameters of the 
zones of inhibition were measured with calipers or automated scanners and were com-
pared to those of the standards (data not shown). Ciprofl oxacin (50 μg mL–1, 150.9 μmol L–1) 
was used as a reference drug.
For determination of the minimum inhibitory concentration (MIC) by the serial plate 
dilution method (28), 5 mg of each test compound was dissolved in 1 mL of DMSO to pre-
pare a stock solution. Serial dilutions were prepared from the stock solution. The plates 
were incubated at 37 °C for 24 h. MIC was the lowest concentration (expressed in μmol L–1) 
of the test compound that resulted in no visible growth on the plates. DMSO was used as 
a solvent control to ensure that the solvent had no eff ect on bacterial growth. Results of 
antibacterial activities are summarized in Table IV.
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Table III. Eff ects of synthesized compounds on the growth of three human tumor cell lines
Compd. GI50 (μmol L–1)
HepG-2 HT29 NCI-H460
4a 10.0 ± 4.2 6.4 ± 2.6 8.4 ± 1.5
4b 0.06 ± 0.004 0.09 ± 0.03 0.1 ± 0.08
4c 18.5 ± 3.8 22.0 ± 2.6 20.0 ± 4.6
5a 2.6 ± 0.2 2.2 ± 0.4 1.6 ± 0.8
5b 1.2 ± 0.2 2.6 ± 0.6 3.2 ± 0.6
5c 4.05 ± 0.2 4.2 ± 0.2 4.8 ± 0.4
6a 4.02 ± 0.2 4.8 ± 0.4 4.6 ± 0.2
6b 0.5 ± 0.01 0.8 ± 0.02 0.4 ± 0.02
6c 5.8 ± 0.8 6. 5 ± 0.4 4.8 ± 0.4
8 8.2 ± 1.9 6.9 ± 0.4 8.6 ± 2.6
9 10.6 ± 1.5 8.4 ± 2.6 12.5 ± 4.2
10 4.4 ± 0.4 4.05 ± 0.2 4.6 ± 0.2
11 2.5 ± 0.6 3.2 ± 0.4 3.01 ± 0.2
12 22.5 ± 3.6 20.6 ± 2.6 16.0 ± 4.6
14 6.05 ± 0.2 8.0 ± 0.8 4.8 ± 0.4
15 0.06 ± 0.008 0.08 ± 0.02 0.1 ± 0.02
16 0.02 ± 0.008 0.04 ± 0.01 0.06 ± 0.04
17 4.4 ± 0.2 8.9 ± 0.8 6.5 ± 0.2
18 12.4 ± 4.4 8.5 ± 2.6 8.7 ± 1.5
19a 8.9 ± 0.8 6. 6 ± 0.4 6.0 ± 0.6
19b 0.02 ± 0.008 0.03 ± 0.007 0.05 ± 0.02
19c 2.4 ± 0.6 1.6 ± 0.8 4.6 ± 0.2
Doxorubicin 0.04 ± 0.008 0.05 ± 0.007 0.09 ± 0.007
Results are given as concentrations that were able to cause 50 % cell growth inhibition (GI50) aft er continuous ex-
posure for 48 h. Mean ± SEM of three independent experiments performed in duplicate.
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Thiophene-2-ethyl carboxylate derivative was the key intermediate for the synthesis 
of a novel series of thieno[3,2-d]pyrimidine and 3-[2-amino-3-cyano-4-phenyl]pyrazolo-5-
(4-chlorophenyl)-thiophene-2-carboxylic acid derivatives to be screened as anticancer and 
antibacterial agents. The synthetic route of target compounds 2–13 is illustrated in Schemes 
Table IV. Minimum inhibitory concentration (MIC, μmol L–1) of newly synthesized compounds
Microorganism
Gram-positive                             Gram-negative
Compd. S. aureus S. bovis C. pneumoniae S. typhi
4a 8 4 5 5
4b 2 3 3 7
4c 12 10 4 4
5a 11 10 10 12
5b 8 8 10 11
5c 9 12 8 8
6a 8 6 6 6
6b 1 2 2 3
6c 10 6 8 8
8 10 8 8 6
9 6 6 8 8
10 2 3 4 4
11 5 4 5 5
12 18 15 16 16
14 6 4 8 8
15 2 2 3 8
16 3 2 1 1
17 12 13 10 10
18 13 13 11 10
19a 14 18 18 16
19b 2 3 3 1
19c 2 2 5 8
Ciprofl oxacin   0.9   0.9     0.9          0.85
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1 and 2. Commercially available 3-amino-5-(4-chlorophenyl)-thiophene-2-carboxylic acid 
(1) underwent esterifi cation with ethanol in the presence of HCl to provide ethyl 3-amino-
5-(4-chlorophenyl)-thiophene-2-carboxylate (2). The latt er was condensed with thiophos-
gene in dry chloroform stirred under refl ux for 5 h to obtain the corresponding 3-isothio-
cyanate 3. Treatment of compound 3 with sulfa drugs in DMF yielded the corresponding 
ethyl-5-(4-chlorophenyl)-3-[N-(substituted)-4-(carbamothioyl)amino-benzenesulfon-
amide] thiophene-2-carboxylate derivatives 4a-c, which underwent intramolecular cycli-
zation by the treatment with hydrazine hydrate to aff ord the corresponding N-aminopy-
rimidine derivatives 5a-c. Triazolopyrimidine derivatives 6a-c were obtained via reaction 
of compounds 5a-c with aromatic aldehyde, namely, p-fl uorobenzaldehyde in acetic acid 
containing sodium acetate. IR and 1H NMR spectra of compounds 6a-c revealed disap-
pearance of the N-amino group. Also, treatment of 5a-c with formic acid aff orded triazo-
lopyrimidine derivatives 7a-c (Scheme 1). 2-Benzyl-6-(4-chlorophenyl)-thieno[3,2-d]pyrimi-
dine-4-one (8) was obtained via reaction of ethyl 3-amino-5-(4-chlorophenyl)
thiophene-2-carboxylate (2) with benzylamine in the presence of triethylorthoformate. 
Compound 2 underwent cyclization in the treatment with hydrazine hydrate in the pres-
ence of triethylorthoformate to aff ord N-aminopyrimidine derivative 9. The structure of 
Scheme 1
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compound 9 was confi rmed by 1H NMR (DMSO-d6), which revealed the absence of triplet 
and quartet patt erns of the ethyl group and appearance of signals at 8.4 ppm for (1H) py-
rimidine. N-aminopyrimidine derivative 9 when reacted with 4-benzylidene-2-phenyl-
4H-oxazol-5-one in dry pyridine gave N-imidazole derivative 10. Triazole-thione deriva-
tive 11 was prepared by treatment of N-amino pyrimidine derivative 9 with thiourea (29).
Structure of compound 11 was supported by elemental analysis, IR and 1H NMR 
spectral data. Its IR spectrum exhibited the absence of CO band and the presence of NH 
band at 3330 cm–1 whereas 1H NMR showed signals at 7.25 (d, 2H, Ar-H), 7.50 (d, 2H, Ar-H), 
7.80 (s, CH thiophene), 9.00 (s, 1H, pyrimidine) and 9.4 ppm (s, 1H, NH, D2O exchangeable).
Thionation of compound 9 by treatment with P2S5 in pyridine gave unexpectedly new 
bis-6,6’-(4-dichlorophenyl)-thieno[2,3-e]pyrimido[3,4-c][1,2,4,5]tetrazine (12) rather than 
the expected monothione derivative (13). IR spectrum of compound 12 showed the absence 
of NH2, while the IR spectrum of compound 13 showed that the NH2 group was still pres-
ent, in addition to the presence of C=S at 1265 cm–1 (Scheme 2). On repeating the same reac-
tion in xylene, the mono thione derivative (13) was obtained based on the IR data, which 
showed the presence of NH2 and C=S bands. 1H NMR revealed signals at d 5.70 ppm for 
NH2 and 13C NMR signal at d 166.81 ppm for C=S. It is important to mention that the new 
compound 12 was prepared according to known reaction conditions (24, 29).
Reaction of 3-amino-5-(4-chlorophenyl)thiophene-2-carboxylic acid (1) with phenacyl 
bromide furnished 5-(4-chlorophenyl)-3-[(2-oxo-2-phenylethyl)amino)]thiophene-2-car-
boxylic acid (14), which upon reaction with malononitrile in sodium ethoxide gave pyrrole 
derivative 15. Compound 15 underwent cyclization upon treatment with acetic anhydride 
Scheme 2
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for a long time (12 h) to give the corresponding pyrazolopyrimidine derivative 16. Under 
the condition of fusion of compound 15 with succinic anhydride, compound 17 was af-
forded. 
Finally, heating of compound 15 with triethylorthoformate in boiling acetic anhydride 
gave the ethylpyrroloimidoformate derivative 18. The latt er underwent cyclization aft er 
treatment with hydrazide derivatives to aff ord products 19a-c with three fused rings 
(Scheme 3).
Antitumor activity and structure a ctivity relationship
The eff ect of newly synthesized compounds was evaluated through in vitro growth of 
three human tumor cell lines representing diff erent tumor types, namely, liver cancer 
(HepG-2), colon cancer (HT-29) and lung cancer (NCI-H460), aft er continuous exposure for 
48 h. The results summarized in Table III show that most of the tested compounds exhib-
ited marked activity compared to doxorubicin. Compounds 16 (GI50 = 0.02, 0.04 and 0.06 
μmol L–1, resp.) and 19b (GI50 = 0.02, 0.03 and 0.05 μmol L–1, resp.) exhibited higher antican-
Scheme 3
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cer activity than doxorubicin (GI50 = 0.04, 0.05 and 0.09 μmol L–1, resp.) against the three 
tumor cell lines. Such high activity of both compounds is att ributed to the presence of pyr-
rolopyrimidine moiety at position 3 in the thiophene derivative 16 but is also due to the 
presence of triazolopyrimidine moiety as in compound 19b. In addition, the presence of 
stronger electron-withdrawing substituents (chloro) in the para-position of the phenyl ring 
might be responsible for enhancing the growth inhibition activity.
Compounds 19a and 19c exhibited moderate to good antitumor activity due to the 
electronic nature of the substituent on the phenyl ring att ached to [1,3,4]-triazolyl moiety: 
in the absence of such substituent as in 19a, moderate inhibition activity was observed, 
while phenyl with an electron donating group (OCH3) att ached to the [1,3,4]-triazolyl moi-
ety as in compound 19c was assumed responsible for good activity.
Structure versus activity revealed that, by changing the substituent on C-3 of the thio-
phene ring, a diff erence in activity was observed. Compounds 4b (GI50 = 0.06, 0.09 and 
0.1 μmol L–1) and 15 (GI50 = 0.06, 0.08 and 0.1 μmol L–1) were almost as active as doxorubicin. 
This activity may be due to the presence of N-(2,6-dimethoxypyrimidin-4-yl)-benzenesul-
fonamide moiety at position 3 in the thiophene derivative 4b and aminopyrrole moiety 
att ached to the thiophene ring in 15. Compounds 5a,b, 6b and 11 exhibited good to moder-
ate inhibition activities with GI50 ranging from 0.4 to 3.2 μmol L–1; activity of these com-
pounds is probably due to the presence of a substituent in the phenyl ring att ached to 
thieno[3,2-d]pyrimidine such as (N-carbamimidoyl and N-pyrimidinyl) benzenesulfon-
amide in 5a,b, [1,2,4]triazolopyrimidine att ached to p-fl uorophenyl in 6b and thioxotri-
azole moiety fused with the pyrimidine ring in 11. Furthermore, compounds 4a, 5c, 6a,c, 
9, 10, 14, 17 and 18 exhibited moderate to low antitumor activity on the three tumor cell 
lines, while compounds 4c and 12 exhibited very low antitumor activity.
Antibacterial activity
Compounds 4a-c, 5a-c, 6a-c, 8-12 and 14-19 were also tested for antibacterial activity 
(Table IV). The antibacterial data indicated that triazolopyrimidine derivatives 6b and 19b 
were the most active compounds, with MIC values of 1–3 μmol L–1 against Gram-positive 
and Gram-negative bacteria, comparable to the standard drug ciprofl oxacin (MIC = 0.9 
μmol L–1). Such high activity may be due to the presence of triazolopyrimidine fused with 
the thiophene ring, in addition to the presence of 4-fl uorophenyl in 6b and 4-chlorophenyl 
in 19b att ached to the triazolopyrimidine.
Also, compounds 4b, 15 and 19c were the most active ones against all bacterial strains 
except Salmonella typhi, with MIC values of 2–5 μmol L–1. The activity of these compounds 
may be att ributed to the presence of N-(2,6-dimethoxypyrimidin-4-yl)-benzenesulfon-
amide moiety att ached to the thiophene ring in 4b, pyrrolo moiety att ached to the thio-
phene ring in 15 and triazolopyrimidine structure in 19c. Furthermore, pyrrolo[2,3-d]py-
rimidine att ached to C3 of the thiophene in compound 16 exhibited high activity, with MIC 
values of 1–3 μmol L–1 against all bacterial strains. Antibacterial activity of compounds 
8–10 increased in dependence on the way of cyclization of the thiophene amino ester de-
rivative 2. Compound 10 exhibited high activity against all Gram-positive and Gram-neg-
ative bacteria with MIC 2-4 μmol L–1, while compounds 8 and 9 exhibited promising activ-
ity against all strains. This activity may be att ributed to the presence of N-imidazole 
moiety at pyrimidine in 10, N-benzyl group in compound 8 and N-amino group at py-
rimidine in compound 9. 
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Compounds 4a, 5a-c, 6a,c, 11 and 14 showed promising activity against all the tested 
bacteria, and this activity may be due to the presence of imido group in 4a, the formation 
of fused N-amino-thienopyrimidine skeleton as in 5a-c, in addition to the presence of 
[1,2,4]triazolopyrimidine in 6a-c and [1,2,4]triazolopyrimidine in 11. Also, the presence of 
oxo-phenylethylamino att ached to the thiophene ring in 14 seems to increase the antibacte-
rial activity. Moreover, compound 4c exhibited good activity against Gram-negative bac-
teria with MIC of 4 μmol L-1 and moderate activity against Gram-positive bacteria, while 
compounds 12, 17, 18 and 19a displayed low activity against all the tested bacteria.
CONCLUSIONS
In the present work, we synthesized some novel thiophenes bearing sulfonamide, 
pyrrole, pyrrolopyrimidine structures, and thieno[3,2-d]pyrimidine derivatives contain-
ing 1,2,4-triazole moiety, and investigated their anticancer and antibacterial activity. 
Among the synthesized compounds, 5-(4-chlorophenyl)-3-(2-methyl-4-oxo-5-phenyl-3,4-
dihydro-7H-pyrrolo[2,3-d]pyrimidine-7-yl)-thiophene-2-carboxylic acid (16) and 
5-(4-chlorophenyl)-{3-(4-chlorophenyl)-9-phenyl-7H-pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]-py-
rimidin-7-yl}-thiophene-2-carboxylic acid (19b) exhibited higher anticancer activity than 
doxorubicin. Furthermore, compounds ethyl 5-(4-chlorophenyl)-3-[N-(2,6-dimethoxypy-
rimidin-4-yl)-4-(carbamothioyl) amino-benzenesulfonamide]thiophene-2-carboxylate (4b) 
and 3-(2-amino-3-cyano-4-phenyl-1H-pyrrol-1-yl)-5-(4-chlorophenyl)-thiophene-2-carbox-
ylic acid (15) exhibited growth inhibition activity nearly as high as that of doxorubicin.
Compounds 4b, 15 and 19b also exhibited good antibacterial activity against Gram-
positive and Gram-negative bacteria along with 5-(4-chlorophenyl)-{3-(4-methoxyphenyl)-
9-phenyl-7H-pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]-pyrimidin-7-yl}-thiophene-2-carboxylic acid 
(19c), 7-(4-chlorophenyl)-2-(4-fl uorophenyl)-1-(N-(2,6-dimethoxypyrimidin-4-yl) benzene-
sulfonamide thieno[3,2-d][1,2,4]triazolo[1,5-a]pyrimidine-5(1H)-thione (6b) and 
6-(4-chlorophenyl)-3-(5-benzylidene-2-phenyl-3,5-dihydro-4H-imidazol-4-one-3-yl)
thieno[3,2-d]pyrimidin-4(3H)-one (10).
Activities of these compounds were strongly dependent on the basic skeleton of the 
molecules and the nature of the heterocyclic ring att ached to the thiophene unit as well as 
on the nature of the substituent at the thiophene unit.
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